As we enter 2026, scientists at The Institute of Cancer Research, London, share the developments expected this year that could soon change how cancer is treated – from technologies designed to deliver ...

Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.

Advocacy engagement: policy and public affairs Our policy priorities Creating a sustainable funding model for research in universities Encouraging international talent to support cancer research ...

Work with the Institute of Cancer Research and help people with cancer. Enquire about trusts and foundations today.

Professor Paul Workman has been awarded an OBE (Officer of the Order of the British Empire) in the New Year Honours list 2026 for services to cancer research. Previously Chief Executive and President ...

Twenty years ago today, the International Genome Sequencing Consortium published the first detailed analysis of the human genome. The paper appeared online in Nature on 15 February 2001, followed by a ...

Cutting edge proton beam therapy is no better than intensity-modulated radiotherapy for treating people with head and neck cancer, according to new research. The nationwide TORPEdO trial funded by ...

These days, in the era of personalised medicine, whenever researchers discover a new cancer drug they are expected to show exactly how it works and to prove that it is exerting its therapeutic effect ...

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned. According to a new modelling study, published in the journal ...

Scientists have shown for the first time that some of the most persistent cancer cells in glioblastoma, a common type of adult brain tumour, rely on a specific enzyme for survival and that inhibiting ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...